

CTI MOLECULAR IMAGING INC  
Form SC TO-T/A  
April 27, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Amendment No. 3 to

**SCHEDULE TO**

Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

**CTI MOLECULAR IMAGING, INC.**

(Name of Subject Company)

**MI MERGER CO.**

**SIEMENS MEDICAL SOLUTIONS USA, INC.**

**SIEMENS AKTIENGESELLSCHAFT**

(Names of Filing Persons (offeror))

Common Stock, Par Value \$0.01 Per Share

(Title of Class of Securities)

22943D105

(CUSIP Number of Class of Securities)

---

**Kenneth R. Meyers, Esq.**

**Siemens Corporation**

**153 East 53rd Street**

**New York, New York 10022**

(Name, address and telephone number of person authorized to receive notices

and communications on behalf of filing persons)

---

*Copy to:*

**Stephen M. Besen, Esq.**

**Shearman & Sterling LLP**

**599 Lexington Avenue**

**New York, New York 10022**

**(212) 848-4000**

---

**Calculation of Filing Fee**

**Transaction Valuation\***

---

\$1,027,149,733.50

**Amount of Filing Fee\*\***

---

\$120,895.53

\* Estimated for purposes of calculating the amount of the filing fee only. Calculated by multiplying \$20.50, the per share tender offer price, by 50,104,867, the sum of the 47,956,322 issued and outstanding shares of common stock as of March 17, 2005 and the 2,148,545 shares of common stock subject to vested options, warrants and deferred stock units.

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC TO-T/A

\*\* Calculated as 0.011770% of the transaction value.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$120,895.53  
Form or Registration No.: Schedule TO

Filing Party: Siemens Aktiengesellschaft  
Date Filed: April 1, 2005

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

---

This Amendment No. 3 to the Tender Offer Statement on Schedule TO (this Amendment No. 3) amends and supplements the Tender Offer Statement on Schedule TO filed on April 1, 2005, as amended and supplemented by Amendment No. 1 to the Tender Offer Statement on Schedule TO filed on April 8, 2005 and Amendment No. 2 to the Tender Offer Statement on Schedule TO filed on April 13, 2005 (as so amended, the Schedule TO), by Siemens Aktiengesellschaft, a corporation organized under the laws of the Federal Republic of Germany (Siemens AG), Siemens Medical Solutions USA, Inc., a Delaware corporation (Parent) and an indirect wholly owned subsidiary of Siemens AG, and MI Merger Co., a Delaware corporation (Purchaser) and a wholly owned subsidiary of Parent. The Schedule TO relates to the offer by Purchaser to purchase all the shares of common stock, par value \$0.01 per share, including the associated Series C Junior Participating Preferred Stock Purchase Rights issued pursuant to the Shareholder Protection Rights Agreement, dated as of May 21, 2002, between the Company (defined below) and SunTrust Bank, as rights agent (together, the Shares), of CTI Molecular Imaging, Inc., a Delaware corporation (the Company), that are issued and outstanding for \$20.50 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 1, 2005 (the Offer to Purchase) and in the related Letter of Transmittal. Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule TO.

Capitalized terms not otherwise defined herein shall have the meanings assigned to them in the Offer to Purchase.

**Item 11. Additional Information**

Item 11 of the Schedule TO is hereby amended and supplemented by including the following:

The putative class action initiated on March 22, 2005 by the City of Monroe Employees Retirement System against the Company and members of the Board in the Chancery Court for Knox County, Tennessee, Sixth Judicial District at Knoxville was removed to the United States District Court for the Eastern District of Tennessee on April 15, 2005. On April 26, 2005, the District Court denied plaintiff's request for a temporary restraining order to enjoin the consummation of the Offer.

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC TO-T/A

---

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 27, 2005

MI MERGER CO.

By: /s/ JAMES RUGER  
Name: **James Ruger**  
Title: **Vice President and Treasurer**

By: /s/ KENNETH R. MEYERS  
Name: **Kenneth R. Meyers**  
Title: **Secretary**

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC TO-T/A

---

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 27, 2005

SIEMENS MEDICAL SOLUTIONS USA, INC.

By: /s/ HERMANN REQUARDT  
Name: **Hermann Requardt**  
Title: **Vice Chairman**

By: /s/ JAMES RUGER  
Name: **James Ruger**  
Title: **Secretary**

Edgar Filing: CTI MOLECULAR IMAGING INC - Form SC TO-T/A

---

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 27, 2005

SIEMENS AKTIENGESELLSCHAFT

By: /s/ HERMANN REQUARDT  
Name: **Hermann Requardt**  
Title: **Group Executive Vice President**

By: /s/ GOETZ STEINHARDT  
Name: **Goetz Steinhardt**  
Title: **Group Executive Vice President**